Evidence map›Paper›PMID 30651148›Full record

ArticleClinical epigenetics2019

Demethylation by low-dose 5-aza-2'-deoxycytidine impairs 3D melanoma invasion partially through miR-199a-3p expression revealing the role of this miR in melanoma.

Cécile Desjobert, Arnaud Carrier, Audrey Delmas, Diego M Marzese, Antoine Daunay, Florence Busato, Arnaud Pillon, Jörg Tost, Joëlle Riond, Gilles Favre and 2 more

Open access · goldAbstract read
In one paragraph

Article in Clinical epigenetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Terahertz radiation and the skin: a review.Journal of biomedical optics · 2021
    Review
  8. The miRNAs Role in Melanoma and in Its Resistance to Therapy.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Cécile DesjobertFRE no. 3600 CNRS, Epigenetic Targeting of Cancer (ETaC), Toulouse, France.
Arnaud CarrierFRE no. 3600 CNRS, Epigenetic Targeting of Cancer (ETaC), Toulouse, France.
Audrey DelmasCancer Research Center of Toulouse, CRCT, Toulouse, France.
Diego M MarzeseDepartment of Translational Molecular Medicine, John Wayne Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA.
Antoine DaunayLaboratory for Functional Genomics, Fondation Jean Dausset - CEPH, Paris, France.
Florence BusatoLaboratory for Epigenetics and Environment, Centre National de la Recherche en Génomique Humaine, CEA, Evry, France.
Arnaud PillonInstitut de Recherche Pierre Fabre, CRDPF, Toulouse, France.
Jörg TostLaboratory for Epigenetics and Environment, Centre National de la Recherche en Génomique Humaine, CEA, Evry, France.
Joëlle RiondFRE no. 3600 CNRS, Epigenetic Targeting of Cancer (ETaC), Toulouse, France.
Gilles FavreCancer Research Center of Toulouse, CRCT, Toulouse, France.
Chantal EtievantCNRS-Pierre Fabre USR3388 ETaC, Toulouse, France.
Paola B ArimondoFRE no. 3600 CNRS, Epigenetic Targeting of Cancer (ETaC), Toulouse, France. paola.arimondo@pasteur.fr.ORCID 0000-0001-5175-4396
Centre National de la Recherche Scientifique · FRCentre de Recherche en Cancérologie de Toulouse · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRFondation Jean Dausset-CEPH · FRPierre Fabre (France) · FRSaint John's Health Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEfficient treatments against metastatic melanoma dissemination are still lacking. Here, we report that low-cytotoxic concentrations of 5-aza-2'-deoxycytidine, a DNA demethylating agent, prevent in vitro 3D invasiveness of metastatic melanoma cells and reduce lung metastasis formation in vivo.

resultsWe unravelled that this beneficial effect is in part due to MIR-199A2 re-expression by promoter demethylation. Alone, this miR showed an anti-invasive and anti-metastatic effect. Throughout integration of micro-RNA target prediction databases with transcriptomic analysis after 5-aza-2'-deoxycytidine treatments, we found that miR-199a-3p downregulates set of genes significantly involved in invasion/migration processes. In addition, analysis of data from melanoma patients showed a stage- and tissue type-dependent modulation of MIR-199A2 expression by DNA methylation.

conclusionsThus, our data suggest that epigenetic- and/or miR-based therapeutic strategies can be relevant to limit metastatic dissemination of melanoma.

Indexed as

AnimalsCell Line, TumorCell SurvivalDecitabineDNA MethylationFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansLung NeoplasmsMelanomaMiceMicroRNAsNeoplasm InvasivenessNeoplasm TransplantationDecitabineMicroRNAsmirn199 microRNA, humanDNA methylationEpigeneticsMelanoma aggressivenessmicroRNA

Identifiers

PMID30651148
PMCPMC6335767
OpenAlexW2915227129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.